Literature DB >> 26459463

[Randomised comparison of stereotactic body radiotherapy versus lobectomy in stage I NSCLC--level I evidence at last?].

Matthias Guckenberger1, Nicolaus Andratschke2.   

Abstract

Mesh：

Year:  2015        PMID： 26459463     DOI： 10.1007/s00066-015-0905-4

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  11 in total

1.  Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.

Authors:  Sashendra Senthi; Frank J Lagerwaard; Cornelis J A Haasbeek; Ben J Slotman; Suresh Senan
Journal:  Lancet Oncol       Date:  2012-06-22       Impact factor: 41.316

2.  Video-assisted thoracic surgery versus open lobectomy for lung cancer: a secondary analysis of data from the American College of Surgeons Oncology Group Z0030 randomized clinical trial.

Authors:  Walter J Scott; Mark S Allen; Gail Darling; Bryan Meyers; Paul A Decker; Joe B Putnam; Robert W McKenna; Rodney J Landrenau; David R Jones; Richard I Inculet; Richard A Malthaner
Journal:  J Thorac Cardiovasc Surg       Date:  2010-02-20       Impact factor: 5.209

3.  High procedure volume is strongly associated with improved survival after lung cancer surgery.

Authors:  Margreet Lüchtenborg; Sharma P Riaz; Victoria H Coupland; Eric Lim; Erik Jakobsen; Mark Krasnik; Richard Page; Michael J Lind; Michael D Peake; Henrik Møller
Journal:  J Clin Oncol       Date:  2013-07-29       Impact factor: 44.544

Review 4.  Which is the optimal biologically effective dose of stereotactic body radiotherapy for Stage I non-small-cell lung cancer? A meta-analysis.

Authors:  Jian Zhang; Fujun Yang; Baosheng Li; Hongsheng Li; Jing Liu; Wei Huang; Dongqing Wang; Yan Yi; Juan Wang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-06-12       Impact factor: 7.038

Review 5.  Stereotactic body radiotherapy in operable patients with stage I NSCLC: where is the evidence?

Authors:  Matthias Guckenberger
Journal:  Expert Rev Anticancer Ther       Date:  2015-03-11       Impact factor: 4.512

6.  The influence of hospital volume on survival after resection for lung cancer.

Authors:  P B Bach; L D Cramer; D Schrag; R J Downey; S E Gelfand; C B Begg
Journal:  N Engl J Med       Date:  2001-07-19       Impact factor: 91.245

7.  Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly.

Authors:  Shervin M Shirvani; Jing Jiang; Joe Y Chang; James W Welsh; Daniel R Gomez; Stephen Swisher; Thomas A Buchholz; Benjamin D Smith
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-09-11       Impact factor: 7.038

8.  Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial.

Authors:  Gail E Darling; Mark S Allen; Paul A Decker; Karla Ballman; Richard A Malthaner; Richard I Inculet; David R Jones; Robert J McKenna; Rodney J Landreneau; Valerie W Rusch; Joe B Putnam
Journal:  J Thorac Cardiovasc Surg       Date:  2011-03       Impact factor: 5.209

9.  Safety and efficacy of stereotactic body radiotherapy for stage 1 non-small-cell lung cancer in routine clinical practice: a patterns-of-care and outcome analysis.

Authors:  Matthias Guckenberger; Michael Allgäuer; Steffen Appold; Karin Dieckmann; Iris Ernst; Ute Ganswindt; Richard Holy; Ursula Nestle; Meinhard Nevinny-Stickel; Sabine Semrau; Florian Sterzing; Andrea Wittig; Nicolaus Andratschke
Journal:  J Thorac Oncol       Date:  2013-08       Impact factor: 15.609

10.  Impact of teaching facility status and high-volume centers on outcomes for lung cancer resection: an examination of 13,469 surgical patients.

Authors:  Michael C Cheung; Kara Hamilton; Recinda Sherman; Margaret M Byrne; Dao M Nguyen; Dido Franceschi; Leonidas G Koniaris
Journal:  Ann Surg Oncol       Date:  2008-07-04       Impact factor: 5.344
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.